

# Stanford

---



## Teri Klein

Professor (Research) of Biomedical Data Science, of Medicine (BMIR) and, by courtesy, of Genetics

### CONTACT INFORMATION

- **Alternate Contact**

Tiffany Murray

**Email** [tiffany.murray@stanford.edu](mailto:tiffany.murray@stanford.edu)

**Tel** 650-725-0659

### Bio

---

### CURRENT ROLE AT STANFORD

Principal Investigator, PharmGKB

Principal Investigator, CPIC

Principal Investigator, PharmCAT

Principal Investigator, ClinGen

### ACADEMIC APPOINTMENTS

- Professor (Research), Biomedical Data Science
- Professor (Research), Medicine - Biomedical Informatics Research
- Professor (Research) (By courtesy), Genetics
- Member, Maternal & Child Health Research Institute (MCHRI)

### HONORS AND AWARDS

- Fellow, American Association for the Advancement of Science (2021)
- Fellow, American College of Medical Genetics and Genomics (2015)
- Fellow, American College of Medical Informatics (2001)

### PROFESSIONAL EDUCATION

- B.A., UC Santa Cruz , Chemistry/Biology (1980)
- Ph.D., UC San Francisco , Medical Information Sciences (1987)

### COMMUNITY AND INTERNATIONAL WORK

- PharmGKB PI
- Co-founder, Pacific Symposium on Biocomputing

## LINKS

- NIH Biosketch in SciENcv: <https://www.ncbi.nlm.nih.gov/myncbi/teri.klein.1/cv/608454/>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research interests extend over the broad spectrum of pharmacogenomics, personalized medicine, computational biology and bioinformatics. Applications include the development of a pharmacogenomics knowledge base, clinical dosing guidelines for pharmacogenomics, annotation of human genome, de novo modeling and the structural basis of disease.

My current research areas involve the studies of the following:

- \* development of an integrated knowledge base about how variation in human genetics leads to variation in our response to drugs
- \* the stability of the collagen triple helix
- \* the relationship and prediction of lethal mutations for the genetic collagenous disease Osteogenesis imperfecta

## Teaching

---

### COURSES

#### 2023-24

- Best practices for developing data science software for clinical and healthcare applications: BIODS 235 (Win)
- Software Engineering For Scientists: BIODS 253 (Win)

#### 2022-23

- Best practices for developing data science software for clinical and healthcare applications: BIODS 235 (Aut)
- Software Engineering For Scientists: BIODS 253 (Win)

#### 2021-22

- Best practices for developing data science software for clinical and healthcare applications: BIODS 235 (Win)
- Software Engineering For Scientists: BIODS 253 (Win)

#### 2020-21

- Software Engineering For Scientists: BIODS 253 (Win)

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Biomedical Informatics (Masters Program)
- Biomedical Informatics (Phd Program)
- Genetics (Phd Program)

## Publications

---

### PUBLICATIONS

- Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. *American journal of human genetics*  
Li, B., Sangkuhl, K., Whaley, R., Woon, M., Keat, K., Whirl-Carrillo, M., Ritchie, M. D., Klein, T. E.  
2023
- PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting. *Clinical pharmacology and therapeutics*

Turner, A. J., Nofziger, C., Ramey, B. E., Ly, R. C., Bousman, C. A., Agúndez, J. A., Sangkuhl, K., Whirl-Carrillo, M., Vanoni, S., Dunnenberger, H. M., Ruano, G., Kennedy, M. A., Phillips, et al  
2023

● **How to Run the Pharmacogenomics Clinical Annotation Tool (PharmCAT).** *Clinical pharmacology and therapeutics*

Li, B., Sangkuhl, K., Keat, K., Whaley, R. M., Woon, M., Verma, S., Dudek, S., Tuteja, S., Verma, A., Whirl-Carrillo, M., Ritchie, M. D., Klein, T. E.  
2022

● **PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge.** *Current protocols*

Gong, L., Whirl-Carrillo, M., Klein, T. E.  
2021; 1 (8): e226

● **An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine.** *Clinical pharmacology and therapeutics*

Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., Klein, T. E.  
2021

● **ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).** *Genetics in medicine : official journal of the American College of Medical Genetics*

Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E., Stewart, D. R., Amendola, L. M., Adelman, K., Bale, S. J., Gollob, M. H., Harrison, S. M., Hershberger, et al  
2021

● **Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).** *Genetics in medicine : official journal of the American College of Medical Genetics*

Miller, D. T., Lee, K., Gordon, A. S., Amendola, L. M., Adelman, K., Bale, S. J., Chung, W. K., Gollob, M. H., Harrison, S. M., Herman, G. E., Hershberger, R. E., Klein, T. E., McKelvey, et al  
2021

● **Expanding evidence leads to new pharmacogenomics payer coverage.** *Genetics in medicine : official journal of the American College of Medical Genetics*

Empey, P. E., Pratt, V. M., Hoffman, J. M., Caudle, K. E., Klein, T. E.  
2021

● **PharmGKB tutorial for pharmacogenomics of drugs potentially used in the context of COVID-19.** *Clinical pharmacology and therapeutics*

Huddart, R., Whirl-Carrillo, M., Altman, R. B., Klein, T. E.  
2020

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.** *Clinical pharmacology and therapeutics*

Theken, K. N., Lee, C. R., Gong, L., Caudle, K. E., Formea, C. M., Gaedigk, A., Klein, T. E., Agundez, J. A., Grosser, T.  
2020

● **PGxMine: Text mining for curation of PharmGKB.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*

Lever, J. n., Barbarino, J. M., Gong, L. n., Huddart, R. n., Sangkuhl, K. n., Whaley, R. n., Whirl-Carrillo, M. n., Woon, M. n., Klein, T. E., Altman, R. B.  
2020; 25: 611–22

● **A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy.** *Clinical pharmacology and therapeutics*

Hicks, J. K., Bishop, J. R., Gammal, R. S., Sangkuhl, K., Bousman, C. A., Leeder, J. S., Llerena, A., Mueller, D. J., Ramsey, L. B., Scott, S. A., Skaar, T. C., Caudle, K. E., Klein, et al  
2019

● **PharmVar GeneReview: CYP2D6.** *Clinical pharmacology and therapeutics*

Nofziger, C., Turner, A. J., Sangkuhl, K., Whirl-Carrillo, M., Agundez, J. A., Black, J. L., Dunnenberger, H. M., Ruano, G., Kennedy, M. A., Phillips, M. S., Hachad, H., Klein, T. E., Gaedigk, et al  
2019

● **Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Huddart, R., Sangkuhl, K., Whirl-Carrillo, M., Klein, T. E.  
2019; 106 (2): 284–86

- **Pharmacogenomics Clinical Annotation Tool (PharmCAT).** *Clinical pharmacology and therapeutics*  
Sangkuhl, K., Whirl-Carrillo, M., Whaley, R. M., Woon, M., Lavertu, A., Altman, R. B., Carter, L., Verma, A., Ritchie, M. D., Klein, T. E.  
2019
- **Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Huddart, R., Fohner, A. E., Whirl-Carrillo, M., Wojcik, G. L., Gignoux, C. R., Popejoy, A. B., Bustamante, C. D., Altman, R. B., Klein, T. E.  
2019; 105 (5): 1256–62
- **Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?** *Clinical pharmacology and therapeutics*  
Huddart, R., Sangkuhl, K., Whirl-Carrillo, M., Klein, T. E.  
2019
- **The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.** *Clinical pharmacology and therapeutics*  
Relling, M. V., Klein, T. E., Gammal, R. S., Whirl-Carrillo, M. n., Hoffman, J. M., Caudle, K. E.  
2019
- **Standardized biogeographic grouping system for annotating populations in pharmacogenetic research.** *Clinical pharmacology and therapeutics*  
Huddart, R., Fohner, A. E., Whirl-Carrillo, M., Wojcik, G. L., Gignoux, C. R., Popejoy, A. B., Bustamante, C. D., Altman, R. B., Klein, T. E.  
2018
- **The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children.** *Clinical pharmacology and therapeutics*  
Gammal, R. S., Caudle, K. E., Quinn, C. T., Wang, W. C., Gaedigk, A., Prows, C. A., Haidar, C. E., Taylor, A. K., Klein, T. E., Sangkuhl, K., Hankins, J. S., Crews, K. R.  
2018
- **PharmCAT: A Pharmacogenomics Clinical Annotation Tool** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Klein, T. E., Ritchie, M. D.  
2018; 104 (1): 19–22
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Goetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl-Carrillo, M., Symmans, W., McLeod, H. L., Ratain, M. J., Zembutsu, H., Gaedigk, A., van Schaik, R. H., Ingle, et al  
2018; 103 (5): 770–77
- **PharmGKB: A worldwide resource for pharmacogenomic information.** *Wiley interdisciplinary reviews. Systems biology and medicine*  
Barbarino, J. M., Whirl-Carrillo, M., Altman, R. B., Klein, T. E.  
2018
- **PharmCAT: A Pharmacogenomics Clinical Annotation Tool.** *Clinical pharmacology and therapeutics*  
Klein, T. E., Ritchie, M. D.  
2017
- **Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics** *GENETICS IN MEDICINE*  
Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., Herman, G. E., Hufnagel, S. B., Klein, T. E., Korf, B. R., McKelvey, K. D., Ormond, K. E., Richards, et al  
2017; 19 (2): 249–255
- **Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).** *Genetics in medicine*  
Caudle, K. E., Dunnberger, H. M., Freimuth, R. R., Peterson, J. F., Burlison, J. D., Whirl-Carrillo, M., Scott, S. A., Rehm, H. L., Williams, M. S., Klein, T. E., Relling, M. V., Hoffman, J. M.  
2016
- **Prediction of CYP2D6 phenotype from genotype across world populations.** *Genetics in medicine*  
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., Leeder, J. S.  
2016

- **Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans** *BLOOD*  
Daneshjou, R., Gamazon, E. R., Burkley, B., Cavallari, L. H., Johnson, J. A., Klein, T. E., Limdi, N., Hillenmeyer, S., Percha, B., Karczewski, K. J., Langae, T., Patel, S. R., Bustamante, et al  
2014; 124 (14): 2298-2305
- **CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Province, M. A., Goetz, M. P., Brauch, H., Flockhart, D. A., Hebert, J. M., Whaley, R., Suman, V. J., Schroth, W., Winter, S., Zembutsu, H., Mushiroda, T., Newman, W. G., Lee, et al  
2014; 95 (2): 216-227
- **Clinical Implementation of Pharmacogenetics: More Than One Gene at a Time** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Johnson, J. A., Klein, T. E., RELLING, M. V.  
2013; 93 (5): 384-385
- **Pharmacogenomics Knowledge for Personalized Medicine** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Whirl-Carrillo, M., McDONAGH, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., Altman, R. B., Klein, T. E.  
2012; 92 (4): 414-417
- **Clopidogrel: A Case for Indication-Specific Pharmacogenetics** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Johnson, J. A., Roden, D. M., Lesko, L. J., Ashley, E., Klein, T. E., Shuldiner, A. R.  
2012; 91 (5): 774-776
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Crews, K. R., Gaedigk, A., Dunnenerger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., Skaar, T. C.  
2012; 91 (2): 321-326
- **CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Relling, M. V., Klein, T. E.  
2011; 89 (3): 464-467
- **Clinical assessment incorporating a personal genome** *LANCET*  
Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., Dudley, J. T., Ormond, K. E., Pavlovic, A., Morgan, A. A., Pushkarev, D., Neff, N. F., Hudgins, et al  
2010; 375 (9725): 1525-1535
- **Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data** *NEW ENGLAND JOURNAL OF MEDICINE*  
Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. M., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J., Caldwell, M. D., Johnson, J. A., Chen, et al  
2009; 360 (8): 753-764
- **Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships** *HUMAN MOLECULAR GENETICS*  
Bodian, D. L., Chan, T., Poon, A., Schwarze, U., Yang, K., Byers, P. H., Kwok, P., Klein, T. E.  
2009; 18 (3): 463-471
- **Knowledge and attitudes on implementing cardiovascular pharmacogenomic testing.** *Clinical and translational science*  
Russell, C., Campion, M., Grove, M. E., Matsuda, K., Klein, T. E., Ashley, E., Naik, H., Wheeler, M. T., Scott, S. A.  
2024; 17 (3): e13737
- **CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods** *GENOME BIOLOGY*  
Jain, S., Bakolitsa, C., Brenner, S. E., Radivojac, P., Moult, J., Repo, S., Hoskins, R. A., Andreoletti, G., Barsky, D., Chellapan, A., Chu, H., Dabbiru, N., Kollipara, et al  
2024; 25 (1): 53
- **From sample to star alleles: a long-read pharmacogenomics pipeline powered by Twist target enrichment and PacBio HiFi sequencing**  
Holt, S., Harting, J., Han, T., Arbiza, L., Kingan, S., Souuppe, A., Zhang, S., Baybayan, P., Lambert, C., Ferrao, H., Li, B., Sangkuhl, K., Woon, et al  
SPRINGERNATURE.2024: 701-702

- **Investigation of genomic and transcriptomic risk factors in clopidogrel response in African Americans.** *medRxiv : the preprint server for health sciences*  
Yang, G., Alarcon, C., Chanfreau, C., Lee, N. H., Friedman, P., Nutescu, E., Tuck, M., O'Brien, T., Gong, L., Klein, T. E., Chang, K. M., Tsao, P. S., Meltzer, et al 2023
- **Highly Scalable Pharmacogenomic Panel Testing with Hybrid Capture and Long-Read Sequencing**  
Gonzaludo, N., Kingan, S., Harting, J., Baybayan, P., Han, T., Arbiza, L., Li, B., Sangkuhl, K., Woon, M., Whaley, R., Whirl-Carrillo, M., Yang, Y., Klein, et al LIPPINCOTT WILLIAMS & WILKINS.2023: 183
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants**  
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J., Strawn, J. R., Singh, A. B., Ruano, G., Mueller, D. J., Tsermpini, E., Brown, J. T., Bell, G. C., Leeder, et al LIPPINCOTT WILLIAMS & WILKINS.2023: 181-183
- **PharmGKB summary: disulfiram pathway.** *Pharmacogenetics and genomics*  
Gonzalez-Suarez, A. D., Thorn, C. F., Whirl-Carrillo, M., Klein, T. E. 2023
- **ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).** *Genetics in medicine : official journal of the American College of Medical Genetics*  
Miller, D. T., Lee, K., Abul-Husn, N. S., Amendola, L. M., Brothers, K., Chung, W. K., Gollob, M. H., Gordon, A. S., Harrison, S. M., Hershberger, R. E., Klein, T. E., Richards, C. S., Stewart, et al 2023: 100866
- **The Role of Epigenomics in Mapping Potential Precursors for Foot and Ankle Tendinopathy: A Systematic Review.** *Foot & ankle specialist*  
Williams, S., Ligas, C., Oloff, L., Klein, T. E. 2023: 19386400231170967
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.** *Clinical pharmacology and therapeutics*  
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, et al 2023
- **Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.** *Journal of translational medicine*  
Verma, S. S., Keat, K., Li, B., Hoffecker, G., Risman, M., Sangkuhl, K., Whirl-Carrillo, M., Dudek, S., Verma, A., Klein, T. E., Ritchie, M. D., Tuteja, S. 2022; 20 (1): 550
- **Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.** *Clinical pharmacology and therapeutics*  
Gammal, R. S., Pirmohamed, M., Somogyi, A. A., Morris, S. A., Formea, C. M., Elchynski, A. L., Oshikoya, K. A., McLeod, H. L., Haidar, C. E., Whirl-Carrillo, M., Klein, T. E., Caudle, K. E., Relling, et al 2022
- **PharmVar GeneFocus: SLCO1B1.** *Clinical pharmacology and therapeutics*  
Ramsey, L. B., Gong, L., Lee, S., Wagner, J. B., Zhou, X., Sangkuhl, K., Adams, S. M., Straka, R. J., Empey, P. E., Boone, E. C., Klein, T. E., Niemi, M., Gaedigk, et al 2022
- **PharmGKB summary: acyclovir/ganciclovir pathway.** *Pharmacogenetics and genomics*  
Maillard, M., Gong, L., Nishii, R., Yang, J. J., Whirl-Carrillo, M., Klein, T. E. 2022; 32 (5): 201-208
- **ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).** *Genetics in medicine : official journal of the American College of Medical Genetics*  
Miller, D. T., Lee, K., Abul-Husn, N. S., Amendola, L. M., Brothers, K., Chung, W. K., Gollob, M. H., Gordon, A. S., Harrison, S. M., Hershberger, R. E., Klein, T. E., Richards, C. S., Stewart, et al 2022; 24 (7): 1407-1414
- **Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation.** *JACC. Advances*

- Thomas, A., Fang, M. C., Kogan, S., Hubbard, C. C., Friedman, P. N., Gong, L., Klein, T. E., Nutescu, E. A., O'Brien, T. J., Tuck, M., Perera, M. A., Schwartz, J. B.  
2022; 1 (2)
- **The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.** *Clinical pharmacology and therapeutics*  
Cooper-DeHoff, R. M., Niemi, M., Ramsey, L. B., Luzum, J. A., Tarkiainen, E. K., Straka, R. J., Gong, L., Tuteja, S., Wilke, R. A., Wadelius, M., Larson, E. A., Roden, D. M., Klein, et al  
2022
  - **Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG).** *Genetics in medicine : official journal of the American College of Medical Genetics*  
Tayeh, M. K., Gaedigk, A., Goetz, M. P., Klein, T. E., Lyon, E., McMillin, G. A., Rentas, S., Shinawi, M., Pratt, V. M., Scott, S. A., ACMG Laboratory Quality Assurance Committee. Electronic address: documents@acmg.net,,  
2022
  - **PharmGKB summary: heparin-induced thrombocytopenia pathway, adverse drug reaction.** *Pharmacogenetics and genomics*  
Miller, E., Norwood, C., Giles, J. B., Huddart, R., Karnes, J. H., Whirl-Carrillo, M., Klein, T. E.  
1800
  - **An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Li, B., Whirl-Carrillo, M., Wright, M. W., Babb, L., Rehm, H. L., Klein, T. E.  
2022; 27: 385-396
  - **PharmVar GeneFocus: CYP3A5.** *Clinical pharmacology and therapeutics*  
Rodriguez-Antona, C., Savieo, J. L., Lauschke, V. M., Sangkuhl, K., Drögemöller, B. I., Wang, D., van Schaik, R. H., Gilep, A. A., Peter, A. P., Boone, E. C., Ramey, B. E., Klein, T. E., Whirl-Carrillo, et al  
2022
  - **Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.** *Clinical pharmacology and therapeutics*  
Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., Hulot, J. S., Roden, D. M., Gaedigk, et al  
2022
  - **Correction to: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).** *Genetics in medicine : official journal of the American College of Medical Genetics*  
Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E., Stewart, D. R., Amendola, L. M., Adelman, K., Bale, S. J., Gollob, M. H., Harrison, S. M., Hershberger, et al  
2021
  - **PharmVar GeneFocus: CYP2C9.** *Clinical pharmacology and therapeutics*  
Sangkuhl, K., Claudio-Campos, K., Cavallari, L. H., Agundez, J., Whirl-Carrillo, M., Duconge, J., Del Tredici, A. L., Wadelius, M., Botton, M. R., Woodahl, E. L., Scott, S. A., Klein, T. E., Pratt, et al  
2021
  - **PharmVar: A Global Resource and Repository for Pharmacogene Variation.** *Clinical pharmacology and therapeutics*  
Gaedigk, A., Casey, S. T., Whirl-Carrillo, M., Miller, N. A., Klein, T. E.  
2021
  - **Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype.** *Clinical pharmacology and therapeutics*  
McDermott, J. H., Wolf, J., Hoshitsuki, K., Huddart, R., Caudle, K. E., Whirl-Carrillo, M., Steyger, P. S., Smith, R. J., Cody, N., Rodriguez-Antona, C., Klein, T. E., Newman, W. G.  
2021
  - **Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.** *Clinical pharmacology and therapeutics*  
Crews, K. R., Monte, A. A., Huddart, R. n., Caudle, K. E., Kharasch, E. D., Gaedigk, A. n., Dunnenberger, H. M., Leeder, J. S., Callaghan, J. T., Samer, C. F., Klein, T. E., Haidar, C. E., Van Driest, et al  
2021

- **PharmVar GeneFocus: CYP2B6.** *Clinical pharmacology and therapeutics*  
Destá, Z. n., El-Boraie, A. n., Gong, L. n., Somogyi, A. A., Lauschke, V. M., Dandara, C. n., Klein, K. n., Miller, N. n., Klein, T. E., Tyndale, R. F., Whirl-Carrillo, M. n., Gaedigk, A. n.  
2021
- **Verifying Nomenclature of DNA Variants in Submitted Manuscripts: Guidance for Journals.** *Human mutation*  
Higgins, J., Dagleish, R., den Dunnen, J. T., Barsh, G., Freeman, P. J., Cooper, D. N., Cullinan, S., Davies, K. E., Dorkins, H., Gong, L., Imoto, I., Klein, T. E., Korf, et al  
2020
- **Pharmacogenetics at Scale: An Analysis of the UK Biobank.** *Clinical pharmacology and therapeutics*  
McInnes, G., Lavertu, A., Sangkuhl, K., Klein, T. E., Whirl-Carrillo, M., Altman, R. B.  
2020
- **Pharmacogenetic information in Swiss drug labels - a systematic analysis.** *The pharmacogenomics journal*  
Jeiziner, C., Suter, K., Wernli, U., Barbarino, J. M., Gong, L., Whirl-Carrillo, M., Klein, T. E., Szucs, T. D., Hersberger, K. E., Meyer Zu Schwabedissen, H. E.  
2020
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.** *Clinical pharmacology and therapeutics*  
Karnes, J. H., Rettie, A. E., Somogyi, A. A., Huddart, R., Fohner, A. E., Formea, C. M., Lee, M. T., Llerena, A., Whirl-Carrillo, M., Klein, T. E., Phillips, E. J., Mintzer, S., Gaedigk, et al  
2020
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.** *Clinical pharmacology and therapeutics*  
Lima, J. J., Thomas, C. D., Barbarino, J., Destá, Z., Van Driest, S. L., El Rouby, N., Johnson, J. A., Cavallari, L. H., Shakhnovich, V., Thacker, D. L., Scott, S. A., Schwab, M., Uppugunduri, et al  
2020
- **PharmVar GeneFocus: CYP2C19.** *Clinical pharmacology and therapeutics*  
Botton, M. R., Whirl-Carrillo, M., Del Tredici, A. L., Sangkuhl, K., Cavallari, L. H., Agundez, J. A., Duconge, J., Lee, M. T., Woodahl, E. L., Claudio-Campos, K., Daly, A. K., Klein, T. E., Pratt, et al  
2020
- **PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics.** *Pharmacogenetics and genomics*  
Mitra-Ghosh, T., Callisto, S. P., Lamba, J. K., Remmel, R. P., Birnbaum, A. K., Barbarino, J. M., Klein, T. E., Altman, R. B.  
2020
- **Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia.** *Pharmacological research*  
Huddart, R. n., Li, G. n., Sangkuhl, K. n., Thorn, C. F., Whirl-Carrillo, M. n., Caudle, K. E., Relling, M. V., Klein, T. E.  
2020; 104838
- **PGxMine: Text mining for curation of PharmGKB**  
Lever, J., Barbarino, J. M., Gong, L., Huddart, R., Sangkuhl, K., Whaley, R., Whirl-Carrillo, M., Woon, M., Klein, T. E., Altman, R. B., Altman, R. B., Dunker, A. K., Hunter, et al  
WORLD SCIENTIFIC PUBL CO PTE LTD.2020: 611-622
- **Review and Consensus on Pharmacogenomic Testing in Psychiatry.** *Pharmacopsychiatry*  
Bousman, C. A., Bengesser, S. A., Aitchison, K. J., Amare, A. T., Aschauer, H. n., Baune, B. T., Asl, B. B., Bishop, J. R., Burmeister, M. n., Chaumette, B. n., Chen, L. S., Cordner, Z. A., Deckert, et al  
2020
- **Effect of CYP3A4\*22 and PPAR-# Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention.** *Genes*  
Bergmeijer, T. O., Yasmina, A. n., Vos, G. J., Janssen, P. W., Hackeng, C. M., Kelder, J. C., Verma, S. S., Ritchie, M. D., Gong, L. n., Klein, T. E., Icpco Investigators, n. n., de Boer, A. n., Klungel, et al  
2020; 11 (9)
- **Genome-wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium (ICPC).** *Clinical pharmacology and therapeutics*

Verma, S. S., Bergmeijer, T. O., Gong, L. n., Reny, J. L., Lewis, J. P., Mitchell, B. D., Alexopoulos, D. n., Aradi, D. n., Altman, R. B., Bliden, K. n., Bradford, Y. n., Campo, G. n., Chang, et al  
2020

● **PharmGKB summary: very important pharmacogene information for CACNA1S.** *Pharmacogenetics and genomics*

Sangkuhl, K., Dirksen, R. T., Alvarellos, M. L., Altman, R. B., Klein, T. E.  
2019

● **PharmGKB summary: sertraline pathway, pharmacokinetics.** *Pharmacogenetics and genomics*

Huddart, R., Hicks, J. K., Ramsey, L. B., Strawn, J. R., Smith, D. M., Bobonis Babilonia, M., Altman, R. B., Klein, T. E.  
2019

● **PharmVar and the Landscape of Pharmacogenetic Resources.** *Clinical pharmacology and therapeutics*

Gaedigk, A., Whirl-Carrillo, M., Pratt, V. M., Miller, N. A., Klein, T. E.  
2019

● **Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients.** *European heart journal. Cardiovascular pharmacotherapy*

Lewis, J. P., Backman, J. D., Reny, J., Bergmeijer, T. O., Mitchell, B. D., Ritchie, M. D., Dery, J., Pakyz, R. E., Gong, L., Ryan, K., Kim, E., Aradi, D., Fernandez-Cadenas, et al  
2019

● **PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*

Stevens, T., Sangkuhl, K., Brown, J. T., Altman, R. B., Klein, T. E.  
2019; 29 (6): 136–54

● **Considerations for pharmacogenomic testing in a health system** *GENETICS IN MEDICINE*

Gammal, R. S., Caudle, K. E., Klein, T. E., Relling, M. V.  
2019; 21 (8): 1886–87

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Desta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., Hockings, J., Myers, A., Swart, M., Tyndale, R. F., Masimirembwa, C., Iwuchukwu, O. F., Chirwa, et al  
2019

● **Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Brown, J. T., Bishop, J. R., Sangkuhl, K., Nurmi, E. L., Mueller, D. J., Dinh, J. C., Gaedigk, A., Klein, T. E., Caudle, K. E., McCracken, J. T., de Leon, J., Leeder, J.  
2019; 106 (1): 94–102

● **PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*

Huddart, R., Altman, R. B., Klein, T. E.  
2019; 29 (4): 91–97

● **The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Gammal, R. S., Caudle, K. E., Quinn, C. T., Wang, W. C., Gaedigk, A., Prows, C. A., Haidar, C. E., Taylor, A. K., Klein, T. E., Sangkuhl, K., Hankins, J. S., Crews, K. R.  
2019; 105 (6): 1300–1302

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Gonsalves, S. G., Dirksen, R. T., Sangkuhl, K., Pulk, R., Alvarellos, M., Vo, T., Hikino, K., Roden, D., Klein, T. E., Poler, S., Patel, S., Caudle, K. E., Gordon, et al  
2019; 105 (6): 1338–44

● **Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Relling, M., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C., Stein, C. M., Moyer, A. M., Evans, W. E., Klein, T. E., Guillermo Antillon-Klussmann, F., Caudle, K. E., Kato, M., Yeoh, et al  
2019; 105 (5): 1095–1105

● **The ACCoNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans** *CTS-CLINICAL AND TRANSLATIONAL SCIENCE*

Friedman, P. N., Shaazuddin, M., Gong, L., Grossman, R. L., Harralson, A. F., Klein, T. E., Lee, N. H., Miller, D. C., Nutescu, E. A., O'Brien, T. J., O'Donnell, P. H., O'Leary, K. J., Tuck, et al  
2019; 12 (3): 209–17

● **Pharmacogene Variation Consortium Gene Introduction: NUDT15** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Yang, J. J., Whirl-Carrillo, M., Scott, S. A., Turner, A. J., Schwab, M., Tanaka, Y., Suarez-Kurtz, G., Schaeffeler, E., Klein, T. E., Miller, N. A., Gaedigk, A.  
2019; 105 (5): 1091–94

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy.** *Clinical pharmacology and therapeutics*

Desta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., Hockings, J., Myers, A., Swart, M., Tyndale, R., Masimirembwa, C., Iwuchukwu, O. F., Chirwa, et al  
2019

● **PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.** *Pharmacogenetics and genomics*

Stevens, T., Sangkuhl, K., Brown, J. T., Altman, R. B., Klein, T. E.  
2019

● **Pharmacogenomics in dermatology: tools for understanding gene-drug associations.** *Seminars in cutaneous medicine and surgery*

Daneshjou, R., Huddart, R., Klein, T. E., Altman, R. B.  
2019; 38 (1): E19–E24

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy.** *Clinical pharmacology and therapeutics*

Brown, J. T., Bishop, J. R., Sangkuhl, K., Nurmi, E. L., Mueller, D. J., Dinh, J. C., Gaedigk, A., Klein, T. E., Caudle, K. E., McCracken, J. T., de Leon, J., Steven Leeder, J.  
2019

● **PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.** *Pharmacogenetics and genomics*

Huddart, R., Altman, R. B., Klein, T. E.  
2019

● **Considerations for pharmacogenomic testing in a health system.** *Genetics in medicine : official journal of the American College of Medical Genetics*

Gammal, R. S., Caudle, K. E., Klein, T. E., Relling, M. V.  
2019

● **The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.** *Journal of neural transmission (Vienna, Austria : 1996)*

Amare, A. T., Schubert, K. O., Tekola-Ayele, F., Hsu, Y., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V., Brockmoller, J., Chen, et al  
2019

● **The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression** *JOURNAL OF NEURAL TRANSMISSION*

Amare, A. T., Schubert, K., Tekola-Ayele, F., Hsu, Y., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V., Brockmoeller, J., Chen, et al  
2019; 126 (1): 35–45

● **The Evolution of PharmVar** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Twist, G. P., Klein, T. E., Miller, N. A., PharmVar Steering Comm  
2019; 105 (1): 29–32

● **Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.** *Clinical and translational science*

Caudle, K. E., Sangkuhl, K. n., Whirl-Carrillo, M. n., Swen, J. J., Haidar, C. E., Klein, T. E., Gammal, R. S., Relling, M. V., Scott, S. A., Hertz, D. L., Guchelaar, H. J., Gaedigk, A. n.  
2019

● **Essential Characteristics of Pharmacogenomics Study Publications** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

- Thorn, C. F., Whirl-Carrillo, M., Hachad, H., Johnson, J. A., McDonagh, E. M., Ratain, M. J., Relling, M. V., Scott, S. A., Altman, R. B., Klein, T. E. 2019; 105 (1): 86–91
- **The ACCoNT Consortium: a model for the discovery, translation and implementation of precision medicine in African Americans.** *Clinical and translational science*  
Friedman, P. N., Shaazuddin, M., Gong, L., Grossman, R. L., Harralson, A. F., Klein, T. E., Lee, N. H., Miller, D. C., Nutescu, E. A., O'Brien, T. J., O'Donnell, P. H., O'Leary, K. J., Tuck, et al  
2018
  - **The Evolution of PharmVar.** *Clinical pharmacology and therapeutics*  
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Twist, G. P., Klein, T. E., Miller, N. A., PharmVar Steering Committee  
2018
  - **Pharmacogene Variation Consortium Gene Introduction: NUDT15.** *Clinical pharmacology and therapeutics*  
Yang, J. J., Whirl-Carrillo, M., Scott, S. A., Turner, A. J., Schwab, M., Tanaka, Y., Suarez-Kurtz, G., Schaeffeler, E., Klein, T. E., Miller, N. A., Gaedigk, A.  
2018
  - **Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.** *Clinical pharmacology and therapeutics*  
Gonsalves, S. G., Dirksen, R. T., Sangkuhl, K., Pulk, R., Alvarellos, M., Vo, T., Hikino, K., Roden, D., Klein, T., Mark Poler, S., Patel, S., Caudle, K. E., Gordon, et al  
2018
  - **Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.** *Clinical pharmacology and therapeutics*  
Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C., Stein, C. M., Moyer, A. M., Evans, W. E., Klein, T. E., Antillon-Klussmann, F. G., Caudle, K. E., Kato, M., Yeoh, et al  
2018
  - **Essential characteristics of pharmacogenomics study publications.** *Clinical pharmacology and therapeutics*  
Thorn, C. F., Whirl-Carrillo, M., Hachad, H., Johnson, J. A., McDonagh, E. M., Ratain, M. J., Relling, M. V., Scott, S. A., Altman, R. B., Klein, T. E.  
2018
  - **PharmGKB summary: oxycodone pathway, pharmacokinetics** *PHARMACOGENETICS AND GENOMICS*  
Huddart, R., Clarke, M., Altman, R. B., Klein, T. E.  
2018; 28 (10): 230–37
  - **Pharmacogenomics Knowledge for Personalized Medicine**  
Klein, T., Ritchie, M.  
NATURE PUBLISHING GROUP.2018: 30–31
  - **PharmGKB summary: clozapine pathway, pharmacokinetics** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Mueller, D. J., Altman, R. B., Klein, T. E.  
2018; 28 (9): 214–22
  - **Substitutions for arginine at position 780 in triple helical domain of the alpha 1 (I) chain alter folding of the type I procollagen molecule and cause osteogenesis imperfecta** *PLOS ONE*  
Makareeva, E., Sun, G., Mirigian, L. S., Mertz, E. L., Vera, J. C., Espinoza, N. A., Yang, K., Chen, D., Klein, T. E., Byers, P. H., Leikin, S.  
2018; 13 (7): e0200264
  - **Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward** *PHARMACOGENOMICS*  
Caudle, K. E., Keeling, N. J., Klein, T. E., Whirl-Carrillo, M., Pratt, V. M., Hoffman, J. M.  
2018; 19 (10): 847–60
  - **PharmGKB: A worldwide resource for pharmacogenomic information** *WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE*  
Barbarino, J. M., Whirl-Carrillo, M., Altman, R. B., Klein, T. E.  
2018; 10 (4)
  - **Pharmacogenomics and big genomic data: from lab to clinic and back again.** *Human molecular genetics*  
Lavertu, A., McInnes, G., Daneshjou, R., Whirl-Carrillo, M., Klein, T. E., Altman, R. B.  
2018; 27 (R1): R72–R78

- **Pharmacogenomics and big genomic data: from lab to clinic and back again** *HUMAN MOLECULAR GENETICS*  
Lavertu, A., McInnes, G., Daneshjou, R., Whirl-Carrillo, M., Klein, T. E., Altman, R. B.  
2018; 27 (R1): R72–R78
- **Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod, H. L., Roden, D. M., Williams, M. S., Green, E. D., Rodriguez, L., Aronson, et al  
2018; 103 (5): 778–86
- **PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*  
Alvarellos, M., Guillemette, C., Altman, R. B., Klein, T. E.  
2018; 28 (5): 127–37
- **PharmGKB summary: clobazam pathway, pharmacokinetics** *PHARMACOGENETICS AND GENOMICS*  
Huddart, R., Leeder, J., Altman, R. B., Klein, T. E.  
2018; 28 (4): 110–15
- **Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Bank, P. D., Caudle, K. E., Swen, J. J., Gammal, R. S., Whirl-Carrillo, M., Klein, T. E., Relling, M. V., Guchelaar, H.  
2018; 103 (4): 599–618
- **Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Phillips, E. J., Sukasem, C., Whirl-Carrillo, M., Mueller, D. J., Dunnaberger, H. M., Chantratita, W., Goldspiel, B., Chen, Y., Carleton, B. C., George, A. L., Mushiroda, T., Klein, T., Gammal, et al  
2018; 103 (4): 574–81
- **Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)** *AMERICAN HEART JOURNAL*  
Bergmeijer, T. O., Reny, J., Pakyz, R. E., Gong, L., Lewis, J. P., Kim, E., Aradi, D., Fernandez-Cadenas, I., Horenstein, R. B., Lee, M., Whaley, R. M., Montaner, J., Franco Gensini, et al  
2018; 198: 152–59
- **Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder** *FRONTIERS IN PSYCHIATRY*  
Amare, A. T., Schubert, K., Tekola-Ayele, F., Hsu, Y., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arold, V., Brockmoeller, J., Chen, et al  
2018; 9: 65
- **THE PHARMACOGENE VARIATION CONSORTIUM: INCORPORATION OF THE HUMAN CYTOCHROME P450 ALLELE NOMENCLATURE DATABASE**  
Gaedigk, A., Klein, T. E., Twist, G. P., Whirl-Carrillo, M., Miller, N. A.  
WILEY.2018: S67
- **The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Gaedigk, A., Ingelman-Sundberg, M., Miller, N. A., Leeder, J., Whirl-Carrillo, M., Klein, T. E., PharmVar Steering Comm  
2018; 103 (3): 399–401
- **Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4(star)22 to Metabolism of Voriconazole"** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Walsh, T. J., Moriyama, B., Penzak, S. R., Klein, T. E., Caudle, K. E.  
2018; 103 (2): 187
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., Schwab, M.  
2018; 103 (2): 210–16

- **New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Relling, M. V., Krauss, R. M., Roden, D. M., Klein, T. E., Fowler, D. M., Terada, N., Lin, L., Riel-Mehan, M., Do, T. P., Kubo, M., Yee, S. W., Johnson, G. T., Giacomini, et al  
2017; 102 (6): 897–902
- **PharmGKB summary: very important pharmacogene information for ABCG2** *PHARMACOGENETICS AND GENOMICS*  
Fohner, A. E., Brackman, D. J., Giacomini, K. M., Altman, R. B., Klein, T. E.  
2017; 27 (11): 420–27
- **Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges** *HUMAN MUTATION*  
Daneshjou, R., Wang, Y., Bromberg, Y., Bovo, S., Martelli, P. L., Babbi, G., Di Lena, P., Casadio, R., Edwards, M., Gifford, D., Jones, D. T., Sundaram, L., Bhat, et al  
2017; 38 (9): 1182–92
- **PharmGKB summary: pazopanib pathway, pharmacokinetics** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Sharma, M. R., Altman, R. B., Klein, T. E.  
2017; 27 (8): 307–12
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Moriyama, B., Obeng, A., Barbarino, J., Penzak, S. R., Henning, S. A., Scott, S. A., Agundez, J. G., Wingard, J. R., McLeod, H. L., Klein, T. E., Cross, S. J., Caudle, K. E., Walsh, et al  
2017; 102 (1): 45–51
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.** *Clinical pharmacology and therapeutics*  
Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, S. R., Henning, S. A., Scott, S. A., Agúndez, J., Wingard, J. R., McLeod, H. L., Klein, T. E., Cross, S. J., Caudle, K. E., Walsh, et al  
2017; 102 (1): 45-51
- **PharmGKB summary: sorafenib pathways** *PHARMACOGENETICS AND GENOMICS*  
Gong, L., Giacomini, M. M., Giacomini, C., Maitland, M. L., Altman, R. B., Klein, T. E.  
2017; 27 (6): 240-246
- **PharmGKB summary: voriconazole pathway, pharmacokinetics** *PHARMACOGENETICS AND GENOMICS*  
Barbarino, J. M., Obeng, A. O., Klein, T. E., Altman, R. B.  
2017; 27 (5): 201-209
- **Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.** *Clinical pharmacology & therapeutics*  
Walsh, T. J., Moriyama, B., Penzak, S. R., Klein, T. E., Caudle, K. E.  
2017
- **Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update.** *Clinical pharmacology & therapeutics*  
Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., Lee, M. T., Gage, B. F., Kimmel, S. E., Perera, M. A., Anderson, J. L., Pirmohamed, M., Klein, et al  
2017
- **Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)** *GENETICS IN MEDICINE*  
Caudle, K. E., Dunnenberger, H. M., Freimuth, R. R., Peterson, J. F., Burlison, J. D., Whirl-Carrillo, M., Scott, S. A., Rehm, H. L., Williams, M. S., Klein, T. E., Relling, M. V., Hoffman, J. M.  
2017; 19 (2): 215-223
- **PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.** *Pharmacogenetics and genomics*  
Fohner, A. E., Sparreboom, A., Altman, R. B., Klein, T. E.  
2017

- "The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems". *Clinical pharmacology & therapeutics*  
Luzum, J. A., Pakyz, R. E., Elsey, A. R., Haidar, C. E., Peterson, J. F., Whirl-Carrillo, M., Handelman, S. K., Palmer, K., Pulley, J. M., Beller, M., Schildcrout, J. S., Field, J. R., Weitzel, et al  
2017
- **PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*  
Fohner, A. E., McDonagh, E. M., Clancy, J. P., Carrillo, M. W., Altman, R. B., Klein, T. E.  
2017; 27 (1): 39-42
- **Prediction of CYP2D6 phenotype from genotype across world populations** *GENETICS IN MEDICINE*  
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., Leeder, J. S.  
2017; 19 (1): 69-76
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron.** *Clinical pharmacology & therapeutics*  
Bell, G. C., Caudle, K. E., Whirl-Carrillo, M., Gordon, R. J., Hikino, K., Prows, C. A., Gaedigk, A., Agundez, J. A., Sadhasivam, S., Klein, T. E., Schwab, M.  
2016
- **Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.** *Clinical pharmacology & therapeutics*  
Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Müller, D. J., Shimoda, K., Bishop, J. R., Kharasch, E. D., Skaar, T. C., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Caudle, et al  
2016
- **PharmGKB summary: very important pharmacogene information for MT-RNR1.** *Pharmacogenetics and genomics*  
Barbarino, J. M., McGregor, T. L., Altman, R. B., Klein, T. E.  
2016; 26 (12): 558-567
- **Evidence and resources to implement pharmacogenetic knowledge for precision medicine.** *American journal of health-system pharmacy*  
Caudle, K. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., Relling, M. V., Klein, T. E.  
2016; 73 (23): 1977-1985
- **Evidence and resources to implement pharmacogenetic knowledge for precision medicine** *AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY*  
Caudle, K. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., Belling, M. V., Klein, T. E.  
2016; 73 (23): 1977-1985
- **The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.** *Translational psychiatry*  
Biernacka, J. M., Sangkuhl, K., Jenkins, G., WHALEY, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V., Brockmöller, J., Chen, C. H., Domschke, K., Hall-Flavin, D. K., Hong, et al  
2016; 6 (11)
- **PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.** *Pharmacogenetics and genomics*  
Fohner, A. E., McDonagh, E. M., Clancy, J. P., Whirl Carrillo, M., Altman, R. B., Klein, T. E.  
2016: -?
- **PharmGKB summary: isoniazid pathway, pharmacokinetics.** *Pharmacogenetics and genomics*  
Klein, D. J., Boukouvala, S., McDonagh, E. M., Shuldiner, S. R., Laurieri, N., Thorn, C. F., Altman, R. B., Klein, T. E.  
2016; 26 (9): 436-444
- **Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans.** *Molecular genetics & genomic medicine*  
Daneshjou, R., Cavallari, L. H., Weekes, P. E., Karczewski, K. J., Drozda, K., Perera, M. A., Johnson, J. A., Klein, T. E., Bustamante, C. D., Roden, D. M., Shaffer, C., Denny, J. C., Zehnder, et al  
2016; 4 (5): 513-520
- **Novel Disease-Drug Database Demonstrating Applicability for Pharmacogenomic-Based Prescribing.** *Clinical pharmacology & therapeutics*  
Whirl-Carrillo, M., Sangkuhl, K., Gong, L., Klein, T. E.  
2016

- **Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC) JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION**  
Hoffman, J. M., Dunnenberger, H. M., Hicks, J. K., Caudle, K. E., Carrillo, M. W., Freimuth, R. R., Williams, M. S., Klein, T. E., Peterson, J. F.  
2016; 23 (4): 796-801
- **Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Journal of the American Medical Informatics Association**  
Hoffman, J. M., Dunnenberger, H. M., Kevin Hicks, J., Caudle, K. E., Whirl Carrillo, M., Freimuth, R. R., Williams, M. S., Klein, T. E., Peterson, J. F.  
2016; 23 (4): 796-801
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clinical pharmacology & therapeutics**  
Gammal, R. S., Court, M. H., Haidar, C. E., Iwuchukwu, O. F., Gaur, A. H., Alvarellos, M., Guillemette, C., Lennox, J. L., Whirl-Carrillo, M., Brummel, S. S., Ratain, M. J., Klein, T. E., Schackman, et al  
2016; 99 (4): 363-369
- **PharmGKB summary: very important pharmacogene information for RYR1 PHARMACOGENETICS AND GENOMICS**  
Alvarellos, M. L., Krauss, R. M., Wilke, R. A., Altman, R. B., Klein, T. E.  
2016; 26 (3): 138-144
- **Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clinical pharmacology & therapeutics**  
Kalman, L. V., Agúndez, J., Appell, M. L., Black, J. L., Bell, G. C., Boukouvala, S., Bruckner, C., Bruford, E., Caudle, K., Coulthard, S. A., Daly, A. K., Tredici, A. D., den Dunnen, et al  
2016; 99 (2): 172-185
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update CLINICAL PHARMACOLOGY & THERAPEUTICS**  
Saito, Y., Stamp, L. K., Caudle, K. E., Hershfield, M. S., McDONAGH, E. M., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Kamatani, N., Goldspiel, B. R., Phillips, E. J., Klein, T. E., Lee, et al  
2016; 99 (1): 36-37
- **Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clinical pharmacology and therapeutics**  
Saito, Y., Stamp, L. K., Caudle, K. E., Hershfield, M. S., McDonagh, E. M., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Kamatani, N., Goldspiel, B. R., Phillips, E. J., Klein, T. E., Lee, et al  
2016; 99 (1): 36-7
- **PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics PHARMACOGENETICS AND GENOMICS**  
Alvarellos, M. L., McDonagh, E. M., Patel, S., McLeod, H. L., Altman, R. B., Klein, T. E.  
2015; 25 (12): 622-630
- **Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. PLoS genetics**  
Dewey, F. E., Grove, M. E., Priest, J. R., Waggett, D., Batra, P., Miller, C. L., Wheeler, M., Zia, A., Pan, C., Karzcewski, K. J., Miyake, C., Whirl-Carrillo, M., Klein, et al  
2015; 11 (10)
- **Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data PLOS GENETICS**  
Dewey, F. E., Grove, M. E., Priest, J. R., Waggett, D., Batra, P., Miller, C. L., Wheeler, M., Zia, A., Pan, C., Karzcewski, K. J., Miyake, C., Whirl-Carrillo, M., Klein, et al  
2015; 11 (10)
- **PharmGKB summary: peginterferon-alpha pathway PHARMACOGENETICS AND GENOMICS**  
Shuldiner, S. R., Gong, L., Muir, A. J., Altman, R. B., Klein, T. E.  
2015; 25 (9): 465-474
- **Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics**  
Parra, E. J., Botton, M. R., Perini, J. A., Krithika, S., Bourgeois, S., Johnson, T. A., Tsunoda, T., Pirmohamed, M., Wadelius, M., Limdi, N. A., Cavallari, L. H., Burmester, J. K., Rettie, et al  
2015; 16 (11): 1253-63
- **PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses PHARMACOGENETICS AND GENOMICS**  
Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., FitzGerald, G. A., Altman, R. B., Klein, T. E.

2015; 25 (8): 416-426

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.** *Clinical pharmacology and therapeutics*

Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., Leeder, J. S., Graham, R. L., Chiulli, D. L., LLerena, A., Skaar, T. C., Scott, S. A., Stingl, et al  
2015; 98 (2): 127-34

● **PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.** *Pharmacogenetics and genomics*

Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., Fitzgerald, G. A., Altman, R. B., Klein, T. E.  
2015; 25 (8): 416-26

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Hicks, J. K., Bishop, J. R., Sangkuhl, K., Mueller, D. J., Ji, Y., Leckband, S. G., Leeder, J. S., GRAHAM, R. L., Chiulli, D. L., Llerena, A., Skaar, T. C., Scott, S. A., Stingl, et al  
2015; 98 (1): 127-134

● **PharmGKB summary: Efavirenz pathway, pharmacokinetics** *PHARMACOGENETICS AND GENOMICS*

McDonagh, E. M., Lau, J. L., Alvarellos, M. L., Altman, R. B., Klein, T. E.  
2015; 25 (7): 363-376

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.** *Clinical pharmacology & therapeutics*

Birdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadée, W., Wang, D., Vinks, A. A., He, Y., Swen, J. J., Leeder, J. S., van Schaik, R., Thummel, et al  
2015; 98 (1): 19-24

● **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Birdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadée, W., Wang, D., Vinks, A. A., He, Y., Swen, J. J., Leeder, J. S., van Schaik, R. H., Thummel, et al  
2015; 98 (1): 19-24

● **ClinGen - The Clinical Genome Resource** *NEW ENGLAND JOURNAL OF MEDICINE*

Rehm, H. L., Berg, J. S., Brooks, L. D., Bustamante, C. D., Evans, J. P., Landrum, M. J., Ledbetter, D. H., Maglott, D. R., Martin, C. L., Nussbaum, R. L., Plon, S. E., Ramos, E. M., Sherry, et al  
2015; 372 (23): 2235-2242

● **Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs** *MAYO CLINIC PROCEEDINGS*

Kaufman, A. L., Spitz, J., Jacobs, M., Sorrentino, M., Yuen, S., Danahey, K., Saner, D., Klein, T. E., Altman, R. B., Ratain, M. J., O'Donnell, P. H.  
2015; 90 (6): 716-729

● **The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response** *TRANSLATIONAL PSYCHIATRY*

Biernacka, J. M., Sangkuhl, K., Jenkins, G., WHALEY, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V., Brockmoeller, J., Chen, C. H., Domschke, K., Hall-Flavin, D. K., Hong, et al  
2015; 5

● **The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.** *Translational psychiatry*

Biernacka, J. M., Sangkuhl, K., Jenkins, G., Whaley, R. M., Barman, P., Batzler, A., Altman, R. B., Arolt, V., Brockmøller, J., Chen, C. H., Domschke, K., Hall-Flavin, D. K., Hong, et al  
2015; 5: e553

● **PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.** *Pharmacogenetics and genomics*

Barbarino, J. M., Kroetz, D. L., Klein, T. E., Altman, R. B.  
2015; 25 (4): 205-221

● **PharmGKB summary: very important pharmacogene information for CFTR.** *Pharmacogenetics and genomics*

McDonagh, E. M., Clancy, J. P., Altman, R. B., Klein, T. E.  
2015; 25 (3): 149-156

- **Enabling the curation of your pharmacogenetic study.** *Clinical pharmacology & therapeutics*  
MCDONAGH, E. M., Whirl-Carrillo, M., Altman, R. B., Klein, T. E.  
2015; 97 (2): 116-119
- **INTERACTIVE GENOTYPE-BASED DOSING GUIDELINES.**  
Whirl-Carrillo, M., Whaley, R. M., Caudle, K. E., Relling, M. V., Altman, R. B., Klein, T. E.  
WILEY-BLACKWELL.2015: S61
- **PharmGKB summary: ibuprofen pathways** *PHARMACOGENETICS AND GENOMICS*  
Mazaleuskaya, L. L., Theken, K. N., Gong, L., Thorn, C. F., FitzGerald, G. A., Altman, R. B., Klein, T. E.  
2015; 25 (2): 96-106
- **PharmGKB summary: very important pharmacogene information for CYP4F2** *PHARMACOGENETICS AND GENOMICS*  
Alvarellos, M. L., Sangkuhl, K., Daneshjou, R., Whirl-Carrillo, M., Altman, R. B., Klein, T. E.  
2015; 25 (1): 41-47
- **A TWENTIETH ANNIVERSARY TRIBUTE TO PSB**  
Hewett, D., Whirl-Carrillo, M., Hunter, L. E., Altman, R. B., Klein, T. E., Altman, R. B., Dunker, A. K., Hunter, L., Ritchie, M. D., Murray, T., Klein, T. E.  
WORLD SCIENTIFIC PUBL CO PTE LTD.2015: 1-7
- **Genome-wide association study of warfarin maintenance dose in a Brazilian sample** *PHARMACOGENOMICS*  
Parra, E. J., Botton, M. R., Perini, J. A., Krithika, S., Bourgeois, S., Johnson, T. A., Tsunoda, T., Pirmohamed, M., Wadelius, M., Limdi, N. A., Cavallari, L. H., Burmester, J. K., Rettie, et al  
2015; 16 (11): 1253-1263
- **Evidence synthesis and guideline development in genomic medicine: current status and future prospects** *GENETICS IN MEDICINE*  
Schully, S. D., Lam, T. K., Dotson, W. D., Chang, C. Q., Aronson, N., Birkeland, M. L., Brewster, S. J., Boccia, S., Buchanan, A. H., Calonge, N., Calzone, K., Djulbegovic, B., Goddard, et al  
2015; 17 (1): 63-67
- **A twentieth anniversary tribute to psb.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Hewett, D., Whirl-Carrillo, M., Hunter, L. E., Altman, R. B., Klein, T. E.  
2015; 20: 1-7
- **Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S., Lee, M. T., Klein, T. E., Callaghan, J. T.  
2014; 96 (5): 542-548
- **PharmGKB summary: gemcitabine pathway.** *Pharmacogenetics and genomics*  
Alvarellos, M. L., Lamba, J., Sangkuhl, K., Thorn, C. F., Wang, L., Klein, D. J., Altman, R. B., Klein, T. E.  
2014; 24 (11): 564-574
- **Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.** *Clinical pharmacology & therapeutics*  
Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S., Lee, M. T., Klein, T. E., Callaghan, J. T.  
2014; 96 (5): 542-548
- **PharmGKB summary: gemcitabine pathway** *PHARMACOGENETICS AND GENOMICS*  
Alvarellos, M. L., Lamba, J., Sangkuhl, K., Thorn, C. F., Wang, L., Klein, D. J., Altman, R. B., Klein, T. E.  
2014; 24 (11): 564-574
- **Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.** *Blood*  
Daneshjou, R., Gamazon, E. R., Burkley, B., Cavallari, L. H., Johnson, J. A., Klein, T. E., Limdi, N., Hillenmeyer, S., Percha, B., Karczewski, K. J., Langae, T., Patel, S. R., Bustamante, et al  
2014; 124 (14): 2298-2305
- **The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., MAXWELL, W. D., McLeod, L., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., Gong, et al

2014; 96 (4): 423-428

- **The clinical pharmacogenetics implementation consortium (CPIC): facilitating the adoption of pharmacogenetics into routine clinical practice and the electronic health record.**

Caudle, K. E., Hoffman, J. M., Whirl-Carrillo, M., Haidar, C. E., Crews, K. R., Klein, T. E., Relling, M. V.  
WILEY-BLACKWELL.2014: E251-E252

- **The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. *Clinical pharmacology and therapeutics***

Ramsey, L. B., Johnson, S. G., Caudle, K. E., Haidar, C. E., Voora, D., Wilke, R. A., Maxwell, W. D., McLeod, H. L., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., Gong, et al  
2014; 96 (4): 423-8

- **PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. *Pharmacogenetics and genomics***

McDonagh, E. M., Thorn, C. F., Callaghan, J. T., Altman, R. B., Klein, T. E.  
2014; 24 (9): 464-476

- **PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. *Pharmacogenetics and genomics***

McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., Klein, T. E.  
2014; 24 (8): 409-425

- **Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium. *Clinical pharmacology & therapeutics***

Province, M. A., Altman, R. B., Klein, T. E.  
2014; 96 (2): 144-146

- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype. *Clinical pharmacology & therapeutics***

RELLING, M. V., MCDONAGH, E. M., Chang, T., Caudle, K. E., McLeod, H. L., Haidar, C. E., Klein, T., Luzzatto, L.  
2014; 96 (2): 169-174

- **PharmGKB summary: tramadol pathway PHARMACOGENETICS AND GENOMICS**

Gong, L., Stamer, U. M., Tzvetkov, M. V., Altman, R. B., Klein, T. E.  
2014; 24 (7): 374-380

- **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype. *Clinical pharmacology & therapeutics***

Clancy, J. P., Johnson, S. G., Yee, S. W., MCDONAGH, E. M., Caudle, K. E., Klein, T. E., Cannavo, M., Giacomini, K. M.  
2014; 95 (6): 592-597

- **PharmGKB summary: very important pharmacogene information for SLC22A1. *Pharmacogenetics and genomics***

Goswami, S., Gong, L., Giacomini, K., Altman, R. B., Klein, T. E.  
2014; 24 (6): 324-328

- **In silico comparative characterization of pharmacogenomic missense variants BMC GENOMICS**

Li, B., Seligman, C., Thusberg, J., Miller, J. L., Auer, J., Whirl-Carrillo, M., Capriotti, E., Klein, T. E., Mooney, S. D.  
2014; 15

- **PharmGKB summary: abacavir pathway. *Pharmacogenetics and genomics***

Barbarino, J. M., Kroetz, D. L., Altman, R. B., Klein, T. E.  
2014; 24 (5): 276-282

- **Genotype-Guided Dosing of Vitamin K Antagonists NEW ENGLAND JOURNAL OF MEDICINE**

Daneshjou, R., Klein, T. E., Altman, R. B.  
2014; 370 (18): 1762-63

- **Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update CLINICAL PHARMACOLOGY & THERAPEUTICS**

Martin, M. A., Hoffman, J. M., Freimuth, R. R., Klein, T. E., Dong, B. J., Pirmohamed, M., Hicks, J. K., Wilkinson, M. R., Haas, D. W., Kroetz, D. L.  
2014; 95 (5): 499-500

- **Genotype-guided dosing of vitamin K antagonists. New England journal of medicine**

- Daneshjou, R., Klein, T. E., Altman, R. B.  
2014; 370 (18): 1762-1763
- **Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update.** *Clinical pharmacology & therapeutics*  
Crews, K. R., Gaedigk, A., Dunnaberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J. T., Sadhasivam, S., Prows, C. A., Kharasch, E. D., Skaar, et al  
2014; 95 (4): 376-382
  - **Clinical interpretation and implications of whole-genome sequencing.** *JAMA*  
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., Merker, J. D., Goldfeder, R. L., Enns, G. M., David, S. P., Pakdaman, N., Ormond, K. E., Caleshu, et al  
2014; 311 (10): 1035-1045
  - **Clinical interpretation and implications of whole-genome sequencing.** *JAMA : the journal of the American Medical Association*  
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., Merker, J. D., Goldfeder, R. L., Enns, G. M., David, S. P., Pakdaman, N., Ormond, K. E., Caleshu, et al  
2014; 311 (10): 1035-1045
  - **PharmGKB summary: very important pharmacogene information for UGT1A1 PHARMACOGENETICS AND GENOMICS**  
Barbarino, J. M., Haidar, C. E., Klein, T. E., Altman, R. B.  
2014; 24 (3): 177-183
  - **PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.** *Pharmacogenetics and genomics*  
Lowenberg, D., Thorn, C. F., Desta, Z., Flockhart, D. A., Altman, R. B., Klein, T. E.  
2014; 24 (2): 133-138
  - **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-alpha-Based Regimens** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Muir, A. J., Gong, L., Johnson, S. G., Lee, M. T., Williams, M. S., Klein, T. E., Caudle, K. E., Nelson, D. R.  
2014; 95 (2): 141-146
  - **Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process.** *Current drug metabolism*  
Caudle, K. E., Klein, T. E., Hoffman, J. M., Muller, D. J., Whirl-Carrillo, M., Gong, L., McDonagh, E. M., Sangkuhl, K., Thorn, C. F., Schwab, M., Agundez, J. A., Freimuth, R. R., Huser, et al  
2014; 15 (2): 209-217
  - **Path-scan: a reporting tool for identifying clinically actionable variants.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Daneshjou, R., Zappala, Z., Kukurba, K., Boyle, S. M., Ormond, K. E., Klein, T. E., Snyder, M., Bustamante, C. D., Altman, R. B., Montgomery, S. B.  
2014; 19: 229-240
  - **PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS**  
Daneshjou, R., Zappala, Z., Kukurba, K., Boyle, S. M., Ormond, K. E., Klein, T. E., Snyder, M., Bustamante, C. D., Altman, R. B., Montgomery, S. B., Altman, R. B., Dunker, A. K., Hunter, et al  
WORLD SCIENTIFIC PUBL CO PTE LTD.2014: 229-40
  - **Re: CYP2D6 genotyping and the use of tamoxifen in breast cancer.** *Journal of the National Cancer Institute*  
Province, M. A., Klein, T. E.  
2014; 106 (2): djt379
  - **PharmGKB summary: mycophenolic acid pathway** *PHARMACOGENETICS AND GENOMICS*  
Lamba, V., Sangkuhl, K., Sanghavi, K., Fish, A., Altman, R. B., Klein, T. E.  
2014; 24 (1): 73-79
  - **PharmGKB summary: venlafaxine pathway** *PHARMACOGENETICS AND GENOMICS*  
Sangkuhl, K., Stingl, J. C., Turpeinen, M., Altman, R. B., Klein, T. E.  
2014; 24 (1): 62-72
  - **PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8** *PHARMACOGENETICS AND GENOMICS*

Aquilante, C. L., Niemi, M., Gong, L., Altman, R. B., Klein, T. E.  
2013; 23 (12): 721-728

• **Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Caudle, K. E., Thorn, C. F., Klein, T. E., Swen, J. J., McLeod, H. L., Diasio, R. B., Schwab, M.  
2013; 94 (6): 640-645

• **PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.** *Pharmacogenetics and genomics*  
Hodoglugil, U., Carrillo, M. W., Hebert, J. M., Karachalioiu, N., Rosell, R. C., Altman, R. B., Klein, T. E.

2013; 23 (11): 636-642

• **PharmGKB summary: tamoxifen pathway, pharmacokinetics.** *Pharmacogenetics and genomics*  
Klein, D. J., Thorn, C. F., Desta, Z., Flockhart, D. A., Altman, R. B., Klein, T. E.

2013; 23 (11): 643-647

• **PharmGKB summary: cyclosporine and tacrolimus pathways** *PHARMACOGENETICS AND GENOMICS*  
Barbarino, J. M., Staatz, C. E., Venkataraman, R., Klein, T. E., Altman, R. B.

2013; 23 (10): 563-585

• **Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., Shuldiner, A. R.  
2013; 94 (3): 317-323

• **PharmGKB summary: methylene blue pathway** *PHARMACOGENETICS AND GENOMICS*  
McDonagh, E. M., Bautista, J. M., Youngster, I., Altman, R. B., Klein, T. E.

2013; 23 (9): 498-508

• **Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.** *Lancet*  
Perera, M. A., Cavallari, L. H., Limdi, N. A., Gamazon, E. R., Konkashbaev, A., Daneshjou, R., Pluzhnikov, A., Crawford, D. C., Wang, J., Liu, N., Tatonetti, N., Bourgeois, S., Takahashi, et al

2013; 382 (9894): 790-796

• **Challenges in the pharmacogenomic annotation of whole genomes.** *Clinical pharmacology & therapeutics*  
Altman, R. B., Whirl-Carrillo, M., Klein, T. E.

2013; 94 (2): 211-213

• **The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Shuldiner, A. R., RELLING, M. V., Peterson, J. F., Hicks, J. K., Freimuth, R. R., Sadee, W., Pereira, N. L., Roden, D. M., Johnson, J. A., Klein, T. E.  
2013; 94 (2): 207-210

• **Challenges in the Pharmacogenomic Annotation of Whole Genomes** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Altman, R. B., Whirl-Carrillo, M., Klein, T. E.

2013; 94 (2): 211-213

• **PharmGKB summary: diuretics pathway, pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Ellison, D. H., Turner, S. T., Altman, R. B., Klein, T. E.

2013; 23 (8): 449-453

• **Pharmacogenetics of warfarin: challenges and opportunities** *JOURNAL OF HUMAN GENETICS*  
Lee, M. T., Klein, T. E.

2013; 58 (6): 334-338

• **Pathway analysis of genome-wide data improves warfarin dose prediction** *BMC GENOMICS*  
Daneshjou, R., Tatonetti, N. P., Karczewski, K. J., Sagreya, H., Bourgeois, S., Drozda, K., Burmester, J. K., Tsunoda, T., Nakamura, Y., Kubo, M., Tector, M., Limdi, N. A., Cavallari, et al  
2013; 14

• **Valproic acid pathway: pharmacokinetics and pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*

- Ghodke-Puranik, Y., Thorn, C. F., Lamba, J. K., Leeder, J. S., Song, W., Birnbaum, A. K., Altman, R. B., Klein, T. E.  
2013; 23 (4): 236-241
- **Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., Hicks, J. K., Schwab, M., Klein, T. E.  
2013; 93 (4): 324-325
  - **Nomenclature for alleles of the thiopurine methyltransferase gene** *PHARMACOGENETICS AND GENOMICS*  
Appell, M. L., Berg, J., Duley, J., Evans, W. E., Kennedy, M. A., Lennard, L., Marinaki, T., McLeod, H. L., Relling, M. V., Schaeffeler, E., Schwab, M., Weinshilboum, R., Yeoh, et al  
2013; 23 (4): 242-248
  - **The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation.** *Clinical pharmacology and therapeutics*  
Shuldiner, A. R., Relling, M. V., Peterson, J. F., Hicks, K., Freimuth, R. R., Sadee, W., Pereira, N. L., Roden, D. M., Johnson, J. A., Klein, T. E.  
2013
  - **Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Hershfield, M. S., Callaghan, J. T., Tassaneeyakul, W., Mushirosa, T., Thorn, C. F., Klein, T. E., Lee, M. T.  
2013; 93 (2): 153-158
  - **EXPRESSION QUANTITATIVE TRAIT LOCI ANALYSIS OF STABLE WARFARIN DOSE IDENTIFIES NOVEL ASSOCIATIONS: FINDING SIGNAL WITHIN THE NOISE** *Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT)*  
Gamazon, E. R., Daneshjou, R., Cavallari, L. H., Limdi, N. A., Wadelius, M., Johnson, J. A., Klein, T. E., Scott, S., Tsunoda, T., Deloukas, P., Altman, R., Cox, N., Perera, et al  
NATURE PUBLISHING GROUP.2013: S27–S27
  - **Improving data and knowledge management to better integrate health care and research.** *Journal of internal medicine*  
Cases, M. n., Furlong, L. I., Albanell, J. n., Altman, R. B., Bellazzi, R. n., Boyer, S. n., Brand, A. n., Brookes, A. J., Brunak, S. n., Clark, T. W., Gea, J. n., Ghazal, P. n., Graf, et al  
2013
  - **Governmental and Academic Efforts to Advance the Field of Pharmacogenomics** *PHARMACOGENOMICS: CHALLENGES AND OPPORTUNITIES IN THERAPEUTIC IMPLEMENTATION*  
Cavallari, L. H., Klein, T. E., Huang, S., Lam, Y. W., Cavallari, L. H.  
2013: 63–88
  - **PharmGKB: the Pharmacogenomics Knowledge Base.** *Methods in molecular biology (Clifton, N.J.)*  
Thorn, C. F., Klein, T. E., Altman, R. B.  
2013; 1015: 311-320
  - **Pathway analysis of genome-wide data improves warfarin dose prediction.** *BMC genomics*  
Daneshjou, R., Tatonetti, N. P., Karczewski, K. J., Sagreiya, H., Bourgeois, S., Drozda, K., Burmester, J. K., Tsunoda, T., Nakamura, Y., Kubo, M., Tector, M., Limdi, N. A., Cavallari, et al  
2013; 14: S11-?
  - **PharmGKB summary: zidovudine pathway** *PHARMACOGENETICS AND GENOMICS*  
Ghodke, Y., Anderson, P. L., Sangkuhl, K., Lamba, J., Altman, R. B., Klein, T. E.  
2012; 22 (12): 891-894
  - **Metformin pathways: pharmacokinetics and pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*  
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., Klein, T. E.  
2012; 22 (11): 820-827
  - **Very important pharmacogene summary for VDR** *PHARMACOGENETICS AND GENOMICS*  
Poon, A. H., Gong, L., Brasch-Andersen, C., Litonjua, A. A., Raby, B. A., Hamid, Q., Laprise, C., Weiss, S. T., Altman, R. B., Klein, T. E.  
2012; 22 (10): 758-763

- **Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Johnson, J. A., Burkley, B. M., Langae, T. Y., Clare-Salzler, M. J., Klein, T. E., Altman, R. B.  
2012; 92 (4): 437-439
- **PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6** *PHARMACOGENETICS AND GENOMICS*  
McDonagh, E. M., Wassenaar, C., David, S. P., Tyndale, R. F., Altman, R. B., Whirl-Carrillo, M., Klein, T. E.  
2012; 22 (9): 695-708
- **PharmGKB summary: very important pharmacogene information for GSTT1** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Ji, Y., Weinshilboum, R. M., Altman, R. B., Klein, T. E.  
2012; 22 (8): 646-651
- **PharmGKB summary: very important pharmacogene information for CYP3A5** *PHARMACOGENETICS AND GENOMICS*  
Lamba, J., Hebert, J. M., Schuetz, E. G., Klein, T. E., Altman, R. B.  
2012; 22 (7): 555-558
- **The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Wilke, R. A., Ramsey, L. B., Johnson, S. G., MAXWELL, W. D., McLeod, H. L., Voora, D., Krauss, R. M., Roden, D. M., Feng, Q., Cooper-DeHoff, R. M., Gong, L., Klein, T. E., Wadelius, et al  
2012; 92 (1): 112-117
- **PharmGKB summary: phenytoin pathway** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Whirl-Carrillo, M., Leeder, J. S., Klein, T. E., Altman, R. B.  
2012; 22 (6): 466-470
- **PharmGKB summary: caffeine pathway** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Aklillu, E., McDonagh, E. M., Klein, T. E., Altman, R. B.  
2012; 22 (5): 389-395
- **Using ODIN for a PharmGKB revalidation experiment** *DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION*  
Rinaldi, F., Clematide, S., Garten, Y., Whirl-Carrillo, M., Gong, L., Hebert, J. M., Sangkuhl, K., Thorn, C. F., Klein, T. E., Altman, R. B.  
2012
- **Celecoxib pathways: pharmacokinetics and pharmacodynamics** *PHARMACOGENETICS AND GENOMICS*  
Gong, L., Thorn, C. F., Bertagnolli, M. M., Grosser, T., Altman, R. B., Klein, T. E.  
2012; 22 (4): 310-318
- **Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Martin, M. A., Klein, T. E., Dong, B. J., Pirmohamed, M., Haas, D. W., Kroetz, D. L.  
2012; 91 (4): 734-738
- **Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes** *CELL*  
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., Cheng, Y., Clark, M. J., Im, et al  
2012; 148 (6): 1293-1307
- **PharmGKB summary: very important pharmacogene information for G6PD** *PHARMACOGENETICS AND GENOMICS*  
McDonagh, E. M., Thorn, C. F., Bautista, J. M., Youngster, I., Altman, R. B., Klein, T. E.  
2012; 22 (3): 219-228
- **PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19** *PHARMACOGENETICS AND GENOMICS*  
Scott, S. A., Sangkuhl, K., Shuldiner, A. R., Hulot, J., Thorn, C. F., Altman, R. B., Klein, T. E.  
2012; 22 (2): 159-165
- **PharmGKB summary: very important pharmacogene information for CYP1A2** *PHARMACOGENETICS AND GENOMICS*  
Thorn, C. F., Aklillu, E., Klein, T. E., Altman, R. B.

2012; 22 (1): 73-77

● **SYSTEMS PHARMACOGENOMICS-BRIDGING THE GAP**

Ritchie, M., Cox, N., Cheng, C., Weiss, S., Klein, T., Altman, R., P-STAR, PGRN Syst Biol Grp, PharmGKB, Altman, R. B., Dunker, A. K., Hunter, L., Murray, T., Klein, T. E.

WORLD SCIENTIFIC PUBL CO PTE LTD.2012: 442

● **PharmGKB summary: carbamazepine pathway PHARMACOGENETICS AND GENOMICS**

Thorn, C. F., Leckband, S. G., Kelsoe, J., Leeder, J. S., Mueller, D. J., Klein, T. E., Altman, R. B.  
2011; 21 (12): 906-910

● **From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource BIOMARKERS IN MEDICINE**

McDonagh, E. M., Whirl-Carrillo, M., Garten, Y., Altman, R. B., Klein, T. E.  
2011; 5 (6): 795-806

● **PharmGKB summary: citalopram pharmacokinetics pathway PHARMACOGENETICS AND GENOMICS**

Sangkuhl, K., Klein, T. E., Altman, R. B.  
2011; 21 (11): 769-772

● **PharmGKB summary: methotrexate pathway PHARMACOGENETICS AND GENOMICS**

Mikkelsen, T. S., Thorn, C. F., Yang, J. J., Ulrich, C. M., French, D., Zaza, G., Dunnenberger, H. M., Marsh, S., McLeod, H. L., Giacomini, K., Becker, M. L., Gaedigk, R., Leeder, et al  
2011; 21 (10): 679-686

● **Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing CLINICAL PHARMACOLOGY & THERAPEUTICS**

Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T., Pirmohamed, M., Wadelius, M., Klein, T. E., Altman, et al  
2011; 90 (4): 625-629

● **Pharmacogenetics: Call to Action CLINICAL PHARMACOLOGY & THERAPEUTICS**

Relling, M. V., Guchelaar, H. J., Roden, D. M., Klein, T. E.  
2011; 90 (4): 507-507

● **PharmGKB summary: very important pharmacogene information for PTGS2 PHARMACOGENETICS AND GENOMICS**

Thorn, C. F., Grosser, T., Klein, T. E., Altman, R. B.  
2011; 21 (9): 607-613

● **Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence PLOS GENETICS**

Dewey, F. E., Chen, R., Cordero, S. P., Ormond, K. E., Caleshu, C., Karczewski, K. J., Whirl-Carrillo, M., Wheeler, M. T., Dudley, J. T., Byrnes, J. K., Cornejo, O. E., Knowles, J. W., Woon, et al  
2011; 7 (9)

● **Platelet aggregation pathway PHARMACOGENETICS AND GENOMICS**

Sangkuhl, K., Shuldiner, A. R., Klein, T. E., Altman, R. B.  
2011; 21 (8): 516-521

● **Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy CLINICAL PHARMACOLOGY & THERAPEUTICS**

Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J., Johnson, J. A., Roden, D. M., Klein, T. E., Shuldiner, A. R.  
2011; 90 (2): 328-332

● **Doxorubicin pathways: pharmacodynamics and adverse effects PHARMACOGENETICS AND GENOMICS**

Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., Altman, R. B.  
2011; 21 (7): 440-446

● **PharmGKB summary: dopamine receptor D2 PHARMACOGENETICS AND GENOMICS**

Mi, H., Thomas, P. D., Ring, H. Z., Jiang, R., Sangkuhl, K., Klein, T. E., Altman, R. B.  
2011; 21 (6): 350-356

- **PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2 PHARMACOGENETICS AND GENOMICS**  
Berlin, D. S., Sangkuhl, K., Klein, T. E., Altman, R. B.  
2011; 21 (5): 308-311
- **PharmGKB summary: fluoropyrimidine pathways PHARMACOGENETICS AND GENOMICS**  
Thorn, C. F., Marsh, S., Carrillo, M. W., McLeod, H. L., Klein, T. E., Altman, R. B.  
2011; 21 (4): 237-242
- **Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein) PHARMACOGENETICS AND GENOMICS**  
Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., Altman, R. B.  
2011; 21 (3): 152-161
- **Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing CLINICAL PHARMACOLOGY & THERAPEUTICS**  
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., Klein, T. E.  
2011; 89 (3): 387-391
- **PharmGKB: very important pharmacogene - HMGCR PHARMACOGENETICS AND GENOMICS**  
Medina, M. W., Sangkuhl, K., Klein, T. E., Altman, R. B.  
2011; 21 (2): 98-101
- **Bisphosphonates pathway PHARMACOGENETICS AND GENOMICS**  
Gong, L., Altman, R. B., Klein, T. E.  
2011; 21 (1): 50-53
- **Molecular dynamics simulations of the full triple helical region of collagen type I provide an atomic scale view of the protein's regional heterogeneity. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing**  
Bodian, D. L., Radmer, R. J., Holbert, S., Klein, T. E.  
2011: 193-204
- **KCNH2 pharmacogenomics summary PHARMACOGENETICS AND GENOMICS**  
Oshiro, C., Thorn, C. F., Roden, D. M., Klein, T. E., Altman, R. B.  
2010; 20 (12): 775-777
- **SLC19A1 pharmacogenomics summary PHARMACOGENETICS AND GENOMICS**  
Yee, S. W., Gong, L., Badagnani, I., Giacomini, K. M., Klein, T. E., Altman, R. B.  
2010; 20 (11): 708-715
- **VKORC1 Pharmacogenomics Summary PHARMACOGENETICS AND GENOMICS**  
Owen, R. P., Gong, L., Sagreya, H., Klein, T. E., Altman, R. B.  
2010; 20 (10): 642-644
- **Thiopurine pathway PHARMACOGENETICS AND GENOMICS**  
Zaza, G., Cheok, M., Krynetskaia, N., Thorn, C., Stocco, G., Hebert, J. M., McLeod, H., Weinshilboum, R. M., Relling, M. V., Evans, W. E., Klein, T. E., Altman, R. B.  
2010; 20 (9): 573-574
- **PharmGKB summary: very important pharmacogene information for CYP2B6 PHARMACOGENETICS AND GENOMICS**  
Thorn, C. F., Lamba, J. K., Lamba, V., Klein, T. E., Altman, R. B.  
2010; 20 (8): 520-523
- **Clopidogrel pathway PHARMACOGENETICS AND GENOMICS**  
Sangkuhl, K., Klein, T. E., Altman, R. B.  
2010; 20 (7): 463-465
- **Very important pharmacogene summary: thiopurine S-methyltransferase PHARMACOGENETICS AND GENOMICS**  
Wang, L., Pelleymounter, L., Weinshilboum, R., Johnson, J. A., Hebert, J. M., Altman, R. B., Klein, T. E.  
2010; 20 (6): 401-405
- **Challenges in the clinical application of whole-genome sequencing LANCET**

Ormond, K. E., Wheeler, M. T., Hudgins, L., Klein, T. E., Butte, A. J., Altman, R. B., Ashley, E. A., Greely, H. T.  
2010; 375 (9727): 1749-1751

● **Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups** *BLOOD*

Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. M., Chen, C., Motsinger-Reif, A., Sagreya, H., Liu, N., Wu, A. H., Gage, B. F., Jorgensen, et al  
2010; 115 (18): 3827-3834

● **Vascular endothelial growth factor pathway** *PHARMACOGENETICS AND GENOMICS*

Maitland, M. L., Lou, X. J., Ramirez, J., Desai, A. A., Berlin, D. S., McLeod, H. L., Weichselbaum, R. R., Ratain, M. J., Altman, R. B., Klein, T. E.  
2010; 20 (5): 346-349

● **Cytochrome P450 2C9-CYP2C9** *PHARMACOGENETICS AND GENOMICS*

Van Booven, D., Marsh, S., McLeod, H., Carrillo, M. W., Sangkuhl, K., Klein, T. E., Altman, R. B.  
2010; 20 (4): 277-281

● **Pharmacogenomics and bioinformatics: PharmGKB** *PHARMACOGENOMICS*

Thorn, C. F., Klein, T. E., Altman, R. B.  
2010; 11 (4): 501-505

● **DNATwist: A Web-Based Tool for Teaching Middle and High School Students About Pharmacogenomics** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Berlin, D. S., Person, M. G., Mittal, A., Oppezzo, M. A., Chin, D. B., Starr, B., Klein, T. E., Schwartz, D. L., Altman, R. B.  
2010; 87 (4): 393-395

● **PharmGKB very important pharmacogene: SLCO1B1** *PHARMACOGENETICS AND GENOMICS*

Oshiro, C., Mangravite, L., Klein, T., Altman, R.  
2010; 20 (3): 211-216

● **PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme** *PHARMACOGENETICS AND GENOMICS*

Thorn, C. F., Klein, T. E., Altman, R. B.  
2010; 20 (2): 143-146

● **Very important pharmacogene summary ADRB2** *PHARMACOGENETICS AND GENOMICS*

Litonjua, A. A., Gong, L., Duan, Q. L., Shin, J., Moore, M. J., Weiss, S. T., Johnson, J. A., Klein, T. E., Altman, R. B.  
2010; 20 (1): 64-69

● **Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium**

Goetz, M. P., Berry, D. A., Klein, T. E.  
AMER ASSOC CANCER RESEARCH.2009: 492S-493S

● **Taxane pathway** *PHARMACOGENETICS AND GENOMICS*

Oshiro, C., Marsh, S., McLeod, H., Carrillo, M. W., Klein, T., Altman, R.  
2009; 19 (12): 979-983

● **Selective serotonin reuptake inhibitors pathway** *PHARMACOGENETICS AND GENOMICS*

Sangkuhl, K., Klein, T. E., Altman, R. B.  
2009; 19 (11): 907-909

● **Clinically Available Pharmacogenomics Tests** *CLINICAL PHARMACOLOGY & THERAPEUTICS*

Flockhart, D. A., Skaar, T., Berlin, D. S., Klein, T. E., Nguyen, A. T.  
2009; 86 (1): 109-113

● **Platinum pathway** *PHARMACOGENETICS AND GENOMICS*

Marsh, S., McLeod, H., Dolan, E., Shukla, S. J., Rabik, C. A., Gong, L., Hernandez-Boussard, T., Lou, X. J., Klein, T. E., Altman, R. B.  
2009; 19 (7): 563-564

● **Antiestrogen pathway (aromatase inhibitor)** *PHARMACOGENETICS AND GENOMICS*

Desta, Z., Nguyen, A., Flockhart, D., Skaar, T., Fletcher, R., Weinshilboum, R., Berlin, D. S., Klein, T. E., Altman, R. B.  
2009; 19 (7): 554-555

- **Cytochrome P450 2D6 PHARMACOGENETICS AND GENOMICS**  
Owen, R. P., Sangkuhl, K., Klein, T. E., Altman, R. B.  
2009; 19 (7): 559-562
- **Etoposide pathway PHARMACOGENETICS AND GENOMICS**  
Yang, J., Bogni, A., Schuetz, E. G., Ratain, M., Dolan, M. E., McLeod, H., Gong, L., Thorn, C., Relling, M. V., Klein, T. E., Altman, R. B.  
2009; 19 (7): 552-553
- **Codeine and morphine pathway PHARMACOGENETICS AND GENOMICS**  
Thorn, C. F., Klein, T. E., Altman, R. B.  
2009; 19 (7): 556-558
- **Warfarin Pharmacogenetics NEW ENGLAND JOURNAL OF MEDICINE**  
Garcia, D. A., Hylek, E.  
2009; 360 (23): 2474-2474
- **Warfarin Pharmacogenetics Reply NEW ENGLAND JOURNAL OF MEDICINE**  
Klein, T. E., Kimmel, S. E., Johnson, J. A.  
2009; 360 (23): 2475
- **COLdb, a Database Linking Genetic Data to Molecular Function in Fibrillar Collagens HUMAN MUTATION**  
Bodian, D. L., Klein, T. E.  
2009; 30 (6): 946-951
- **New feature: pathways and important genes from PharmGKB PHARMACOGENETICS AND GENOMICS**  
Elchelbaum, M., Altman, R. B., Ratain, M., Klein, T. E.  
2009; 19 (6): 403-403
- **Very important pharmacogene summary: sulfotransferase 1A1 PHARMACOGENETICS AND GENOMICS**  
Hildebrandt, M., Adjei, A., Weinshilboum, R., Johnson, J. A., Berlin, D. S., Klein, T. E., Altman, R. B.  
2009; 19 (6): 404-406
- **New feature: pathways and important genes from PharmGKB. Pharmacogenetics and genomics**  
Eichelbaum, M. n., Altman, R. B., Ratain, M. n., Klein, T. E.  
2009; 19 (6): 403
- **PharmGKB: an integrated resource of pharmacogenomic data and knowledge. Current protocols in bioinformatics / editorial board, Andreas D. Baxevanis ... [et al.]**  
Gong, L., Owen, R. P., Gor, W., Altman, R. B., Klein, T. E.  
2008; Chapter 14: Unit14 7-?
- **Predicting the clinical lethality of osteogenesis imperfecta from collagen glycine mutations BIOCHEMISTRY**  
Bodian, D. L., Madhan, B., Brodsky, B., Klein, T. E.  
2008; 47 (19): 5424-5432
- **Natural variation in four human collagen genes across an ethnically diverse population GENOMICS**  
Chan, T., Poon, A., Basu, A., Addleman, N. R., Chen, J., Phong, A., Byers, P. H., Klein, T. E., Kwok, P.  
2008; 91 (4): 307-314
- **PharmGKB and the international warfarin pharmacogenetics consortium: The changing role for pharmacogenomic databases and single-drug pharmacogenetics HUMAN MUTATION**  
Owen, R. P., Altman, R. B., Klein, T. E.  
2008; 29 (4): 456-460
- **An XML-based interchange format for genotype-phenotype data HUMAN MUTATION**  
Whirl-Carrillo, M., Woon, M., Thorn, C. E., Klein, T. E., Altman, R. B.  
2008; 29 (2): 212-219
- **The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge NUCLEIC ACIDS RESEARCH**

- Hernandez-Boussard, T., Whirl-Carrillo, M., Hebert, J. M., Gong, L., Owen, R., Gong, M., Gor, W., Liu, F., Truong, C., Whaley, R., Woon, M., Zhou, T., Altman, et al  
2008; 36: D913-D918
- **PharmGKB: UNDERSTANDING THE EFFECTS OF INDIVIDUAL GENETIC VARIANTS** *DRUG METABOLISM REVIEWS*  
Sangkuhl, K., Berlin, D. S., Altman, R. B., Klein, T. E.  
2008; 40 (4): 539-551
  - **Folding and misfolding of the collagen triple helix: Markov analysis of molecular dynamics simulations** *BIOPHYSICAL JOURNAL*  
Park, S., Klein, T. E., Pande, V. S.  
2007; 93 (12): 4108-4115
  - **The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB)** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Owen, R. P., Klein, T. E., Altman, R. B.  
2007; 82 (4): 472-475
  - **The Pharmacogenetics Research Network: From SNP discovery to clinical drug response** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Giacomini, K. M., Brett, C. M., Altman, R. B., Benowitz, N. L., Dolan, M. E., Flockhart, D. A., Johnson, J. A., Hayes, D. F., Klein, T., Krauss, R. M., Kroetz, D. L., McLeod, H. L., Nguyen, et al  
2007; 81 (3): 328-345
  - **Biomedical informatics training at Stanford in the 21st century** *JOURNAL OF BIOMEDICAL INFORMATICS*  
Altman, R. B., Klein, T. E.  
2007; 40 (1): 55-58
  - **The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge** *CLINICAL PHARMACOLOGY & THERAPEUTICS*  
Hodge, A. E., Altman, R. B., Klein, T. E.  
2007; 81 (1): 21-24
  - **Integrating large-scale genotype and phenotype data** *OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY*  
Hernandez-Boussard, T., Woon, M., Klein, T. E., Altman, R. B.  
2006; 10 (4): 545-554
  - **Pharmacogenomics: The relevance of emerging genotyping technologies.** *MLO: medical laboratory observer*  
Hernandez-Boussard, T., Klein, T. E., Altman, R. B.  
2006; 38 (3): 24-?
  - **Triple helical structure and stabilization of collagen-like molecules with 4(R)-hydroxyproline in the Xaa position** *BIOPHYSICAL JOURNAL*  
Radmer, R. J., Klein, T. E.  
2006; 90 (2): 578-588
  - **A new set of molecular mechanics parameters for hydroxyproline and its use in molecular dynamics simulations of collagen-like peptides** *JOURNAL OF COMPUTATIONAL CHEMISTRY*  
Park, S., Radmer, R. J., Klein, T. E., Pande, V. S.  
2005; 26 (15): 1612-1616
  - **A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge** *JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION*  
Rubin, D. L., Thorn, C. F., Klein, T. E., Altman, R. B.  
2005; 12 (2): 121-129
  - **PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base.** *Methods in molecular biology (Clifton, N.J.)*  
Thorn, C. F., Klein, T. E., Altman, R. B.  
2005; 311: 179-191
  - **An "omics" view of drug development** *DRUG DEVELOPMENT RESEARCH*  
Altman, R. B., Rubin, D. L., Klein, T. E.  
2004; 62 (2): 81-85
  - **Severity of osteogenesis imperfecta and structure of a collagen-like peptide modeling a lethal mutation site** *BIOCHEMISTRY*  
Radmer, R. J., Klein, T. E.

2004; 43 (18): 5314-5323

● **PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base** *PHARMACOGENOMICS JOURNAL*

Klein, T. E., Altman, R. B.

2004; 4 (1): 1-1

● **A resource to acquire and summarize pharmacogenetics knowledge in the literature** *11th World Congress on Medical Informatics*

Rubin, D. L., Carrillo, M., Woon, M., Conroy, J., Klein, T. E., Altman, R. B.

I O S PRESS.2004: 793-797

● **Microenvironment analysis and identification of magnesium binding sites in RNA** *NUCLEIC ACIDS RESEARCH*

Banatao, D. R., Altman, R. B., Klein, T. E.

2003; 31 (15): 4450-4460

● **Analysis of mutations in the COLIA1 gene with second-order rule induction** *INTERNATIONAL JOURNAL OF PATTERN RECOGNITION AND ARTIFICIAL INTELLIGENCE*

Hewett, R., Leuchner, J., Mooney, S. D., Klein, T. E.

2003; 17 (5): 721-740

● **WebFEATURE: an interactive web tool for identifying and visualizing functional sites on macromolecular structures** *NUCLEIC ACIDS RESEARCH*

Liang, M. P., Banatao, D. R., Klein, T. E., Brutlag, D. L., Altman, R. B.

2003; 31 (13): 3324-3327

● **A functional analysis of disease-associated mutations in the androgen receptor gene** *NUCLEIC ACIDS RESEARCH*

Mooney, S. D., Klein, T. E., Altman, R. B., Trifiro, M. A., GOTTLIEB, B.

2003; 31 (8)

● **Indexing pharmacogenetic knowledge on the World Wide Web** *PHARMACOGENETICS*

Altman, R. B., Flockhart, D. A., Sherry, S. T., Oliver, D. E., Rubin, D. L., Klein, T. E.

2003; 13 (1): 3-5

● **A personalized and automated dbSNP surveillance system** *2nd International Computational Systems Bioinformatics Conference*

Liu, S., Lin, S., Woon, M., Klein, T. E., Altman, R. B.

IEEE COMPUTER SOC.2003: 132-136

● **Structural models of osteogenesis imperfecta-associated variants in the COL1A1 gene** *MOLECULAR & CELLULAR PROTEOMICS*

Mooney, S. D., Klein, T. E.

2002; 1 (11): 868-875

● **Conformational preferences of substituted prolines in the collagen triple helix** *BIOPOLYMERS*

Mooney, S. D., Kollman, P. A., Klein, T. E.

2002; 64 (2): 63-71

● **A multidomain TIGR/olfactomedin protein family with conserved structural similarity in the N-terminal region and conserved motifs in the C-terminal region** *MOLECULAR & CELLULAR PROTEOMICS*

Green, M. L., Klein, T. E.

2002; 1 (5): 394-403

● **PharmGKB: The Pharmacogenetics Knowledge Base** *NUCLEIC ACIDS RESEARCH*

Hewett, M., Oliver, D. E., Rubin, D. L., Easton, K. L., Stuart, J. M., Altman, R. B., Klein, T. E.

2002; 30 (1): 163-165

● **The functional importance of disease-associated mutation** *BMC BIOINFORMATICS*

Mooney, S. D., Klein, T. E.

2002; 3

● **Automating data acquisition into ontologies from pharmacogenetics relational data sources using declarative object definitions and XML.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*

Rubin, D. L., Hewett, M., Oliver, D. E., Klein, T. E., Altman, R. B.

2002: 88-99

- **Ontology development for a pharmacogenetics knowledge base.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Oliver, D. E., Rubin, D. L., Stuart, J. M., Hewett, M., Klein, T. E., Altman, R. B.  
2002: 65-76
- **Challenges for biomedical informatics and pharmacogenomics** *ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY*  
Altman, R. B., Klein, T. E.  
2002; 42: 113-133
- **Similarities and differences between the TIGR and olfactomedin proteins.**  
Green, M. L., Do, H., Polansky, J. R., Nguyen, T. D., Klein, T. E.  
ASSOC RESEARCH VISION OPHTHALMOLOGY INC.2001: S656-S656
- **Computed free energy differences between point mutations in a collagen-like peptide** *BIOPOLYMERS*  
Mooney, S. D., Huang, C. C., Kollman, P. A., Klein, T. E.  
2001; 58 (3): 347-353
- **ViewFeature: integrated feature analysis and visualization.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Banatao, D. R., Huang, C. C., Babbitt, P. C., Altman, R. B., Klein, T. E.  
2001: 240-250
- **Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base.** *pharmacogenomics journal*  
Klein, T. E., Chang, J. T., Cho, M. K., Easton, K. L., FERGERSON, R., Hewett, M., Lin, Z., Liu, Y., Liu, S., Oliver, D. E., Rubin, D. L., SHAFA, F., Stuart, et al  
2001; 1 (3): 167-170
- **Integrated tools for structural and sequence alignment and analysis.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Huang, C. C., Novak, W. R., Babbitt, P. C., Jewett, A. I., Ferrin, T. E., Klein, T. E.  
2000: 230-241
- **Macromolecular docking of a three-body system: The recognition of human growth hormone by its receptor** *PROTEIN SCIENCE*  
Hendrix, D. K., Klien, T. E., Kuntz, I. D.  
1999; 8 (5): 1010-1022
- **Computational investigations of structural changes resulting from point mutations in a collagen-like peptide** *BIOPOLYMERS*  
Klein, T. E., Huang, C. C.  
1999; 49 (2): 167-183
- **Quantitative structure-activity relationships of 2,4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase** *JOURNAL OF MEDICINAL CHEMISTRY*  
Selassie, C. D., Gan, W. X., Kallander, L. S., Klein, T. E.  
1998; 41 (22): 4261-4272
- **The object technology framework: an object-oriented interface to molecular data and its application to collagen.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Huang, C. C., Couch, G. S., Pettersen, E. F., Ferrin, T. E., Howard, A. E., Klein, T. E.  
1998: 349-361
- **CONIC - A FAST RENDERER FOR SPACE-FILLING MOLECULES WITH SHADOWS** *JOURNAL OF MOLECULAR GRAPHICS*  
Huang, C. C., Pettersen, E. F., Klein, T. E., Ferrin, T. E., LANGRIDGE, R.  
1991; 9 (4): 230-?
- **SEPARATION OF ELECTRONIC AND HYDROPHOBIC EFFECTS FOR THE PAPAIN HYDROLYSIS OF SUBSTITUTED N-BENZOYLGlycine ESTERS** *BIOCHIMICA ET BIOPHYSICA ACTA*  
Compadre, C. M., Hansch, C., Klein, T. E., PETRIDOUFISCHER, J., Selassie, C. D., Smith, R. N., Steinmetz, W., Yang, C. Z., Yang, G. Z.  
1991; 1079 (1): 43-52
- **QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS AND MOLECULAR GRAPHICS IN EVALUATION OF ENZYME LIGAND INTERACTIONS** *METHODS IN ENZYMOLOGY*  
Hansch, C., Klein, T. E.  
1991; 202: 512-543

- **THE STRUCTURE-ACTIVITY RELATIONSHIP OF THE PAPAIN HYDROLYSIS OF N-BENZOYLGlycine ESTERS** *BIOCHIMICA ET BIOPHYSICA ACTA*  
Compadre, C. M., Hansch, C., Klein, T. E., LANGRIDGE, R.  
1990; 1038 (2): 158-163
- **A REAL-TIME MALLEABLE MOLECULAR-SURFACE** *JOURNAL OF MOLECULAR GRAPHICS*  
Klein, T. E., Huang, C. C., Pettersen, E. F., Couch, G. S., Ferrin, T. E., LANGRIDGE, R.  
1990; 8 (1): 16-?
- **QSAR AND MOLECULAR GRAPHICS IN DRUG DESIGN** *ALFRED BENZON SYMP ON FRONTIERS IN DRUG RESEARCH : CRYSTALLOGRAPHIC AND COMPUTATIONAL METHODS*  
Hansch, C., Klein, T.  
MUNKSGAARD.1990: 327-338
- **ON THE STRUCTURE SELECTIVITY PROBLEM IN DRUG DESIGN - A COMPARATIVE-STUDY OF BENZYL PYRIMIDINE INHIBITION OF VERTEBRATE AND BACTERIAL DIHYDROFOLATE-REDUCTASE VIA MOLECULAR GRAPHICS AND QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS** *JOURNAL OF MEDICINAL CHEMISTRY*  
Selassie, C. D., Fang, Z. X., Li, R. L., Hansch, C., Debnath, G., Klein, T. E., LANGRIDGE, R., KAUFMAN, B. T.  
1989; 32 (8): 1895-1905
- **INHIBITION OF CARBONIC-ANHYDRASE BY SUBSTITUTED BENZENESULFONAMIDES - A REINVESTIGATION BY QSAR AND MOLECULAR GRAPHICS ANALYSIS** *QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS*  
Carotti, A., RAGUSEO, C., Campagna, F., LANGRIDGE, R., Klein, T. E.  
1989; 8 (1): 1-10
- **The structure selectivity problem in drug design with respect to antifolates.** *Progress in clinical and biological research*  
Dias Selassie, C., Li, R. L., Hansch, C. H., Klein, T., LANGRIDGE, R., KAUFMAN, B. T., FREISHEIM, J., KHALWAJA, T.  
1989; 291: 341-344
- **QSAR ANALYSIS OF THE SUBTILISIN HYDROLYSIS OF X-PHENYL HIPPURATES .2. A STUDY OF SUBTILISIN BPN'** *CHEMICO-BIOLOGICAL INTERACTIONS*  
Carotti, A., RAGUSEO, C., Klein, T. E., LANGRIDGE, R., Hansch, C.  
1988; 67 (3-4): 171-?
- **CONCANAVALIN X-PHENYL BETA-D-GLUCOPYRANOSIDE INTERACTIONS - A MOLECULAR GRAPHICS-QSAR ANALYSIS** *FARMACO-EDIZIONE SCIENTIFICA*  
Recanatini, M., Klein, T. E., LANGRIDGE, R., Hansch, C.  
1987; 42 (12): 879-891
- **CHYMOTRYPSIN HYDROLYSIS OF X-PHENYL HIPPURATES - A QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP AND MOLECULAR GRAPHICS ANALYSIS** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Morgenstern, L., Recanatini, M., Klein, T. E., Steinmetz, W., Yang, C. Z., LANGRIDGE, R., Hansch, C.  
1987; 262 (22): 10767-10772
- **PHOTOAFFINITY ANALOGS OF METHOTREXATE AS FOLATE ANTAGONIST BINDING PROBES .1. PHOTOAFFINITY-LABELING OF MURINE L1210 DIHYDROFOLATE-REDUCTASE AND AMINO-ACID-SEQUENCE OF THE BINDING REGION** *BIOCHEMISTRY*  
Price, E. M., Smith, P. L., Klein, T. E., FREISHEIM, J. H.  
1987; 26 (15): 4751-4756
- **MOLECULAR GRAPHICS AND QSAR IN THE STUDY OF ENZYME LIGAND INTERACTIONS - ON THE DEFINITION OF BIORECEPTORS** *ACCOUNTS OF CHEMICAL RESEARCH*  
Hansch, C., Klein, T. E.  
1986; 19 (12): 392-400
- **A QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP AND MOLECULAR GRAPHICS ANALYSIS OF HYDROPHOBIC EFFECTS IN THE INTERACTIONS OF INHIBITORS WITH ALCOHOL-DEHYDROGENASE** *JOURNAL OF MEDICINAL CHEMISTRY*  
Hansch, C., Klein, T., MCCLARIN, J., LANGRIDGE, R., Cornell, N. W.  
1986; 29 (5): 615-620
- **INHIBITION OF CHICKEN LIVER DIHYDROFOLATE-REDUCTASE BY 5-(SUBSTITUTED BENZYL)-2,4-DIAMINOPYRIMIDINES - A QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP AND GRAPHICS ANALYSIS** *JOURNAL OF MEDICINAL CHEMISTRY*

Selassie, C. D., Fang, Z. X., Li, R. L., Hansch, C., Klein, T., LANGRIDGE, R., KAUFMAN, B. T.  
1986; 29 (5): 621-626

• **QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS AND MOLECULAR GRAPHICS IN LIGAND RECEPTOR INTERACTIONS - AMIDINE INHIBITION OF TRYPSIN** *MOLECULAR PHARMACOLOGY*

Recanatini, M., Klein, T., Yang, C. Z., MCCLARIN, J., LANGRIDGE, R., Hansch, C.  
1986; 29 (4): 436-446

• **COMPUTER-ASSISTED DRUG RECEPTOR MAPPING ANALYSIS ACS SYMPOSIUM SERIES**

Klein, T. E., Huang, C., Ferrin, T. E., LANGRIDGE, R., Hansch, C.  
1986; 306: 147-158

• **A QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP AND MOLECULAR GRAPHICS STUDY OF CARBONIC-ANHYDRASE INHIBITORS** *MOLECULAR PHARMACOLOGY*

Hansch, C., MCCLARIN, J., Klein, T., LANGRIDGE, R.  
1985; 27 (5): 493-498